載入中
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
前收盤價
US$13.65
+US$0.22 · +1.64%
盤中時間採用ET。市場資料可能有所延遲。
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.
日內區間
目前US$13.65
52週區間
目前US$13.65
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5.9萬 USD | 44.1萬 USD | 192.4萬 USD | 1805.1萬 USD | 539.8萬 USD |
| 銷貨成本 | — | −36.6萬 USD | 128.4萬 USD | 343.4萬 USD | 149.1萬 USD |
| 毛利 | 5.9萬 USD | 80.7萬 USD | 64萬 USD | 1461.7萬 USD | 390.7萬 USD |
| 研究與開發 | 5008.4萬 USD | 5207.8萬 USD | 1378.4萬 USD | 3130.8萬 USD | 5983.5萬 USD |
| 銷售、一般及管理費用 | 2290萬 USD | 1724.1萬 USD | 1030萬 USD | 2071.1萬 USD | 2465.8萬 USD |
| 營業費用 | 7298.4萬 USD | 6931.9萬 USD | 2799.1萬 USD | 5205.7萬 USD | 8604.1萬 USD |
| 利息收入 | 435.1萬 USD | 331.7萬 USD | — | — | — |
| 利息支出 | — | — | 341.7萬 USD | 417萬 USD | 239.1萬 USD |
| 折舊和攤銷 | 34.4萬 USD | 16.9萬 USD | 15.8萬 USD | 16.6萬 USD | 165.7萬 USD |
| 營業利益 | −7292.5萬 USD | −6851.2萬 USD | −2735.1萬 USD | −3744萬 USD | −8213.4萬 USD |
| 淨利 | −7825.9萬 USD | −3512.9萬 USD | −3154.4萬 USD | −4165.8萬 USD | −8437.6萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$44.71
上漲空間 227.55%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年12月29日 | 1:240 | — | — |
股票分割 | 2022年7月8日 | 1:12 | — | — |
已生效 2023年12月29日
1:240
已生效 2022年7月8日
1:12
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3240.41萬0.00%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI2001.71萬0.20%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1802.32萬0.02%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF1050.04萬0.01%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO464.49萬0.03%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA331.94萬0.02%218.24億 USD0.03%US$32.79+0.40%
iShares Russell 2000 Growth ETFIWO319.6萬0.02%139.17億 USD0.24%US$356.78+0.94%
Fidelity Enhanced Small Cap ETFFESM310.28萬0.05%64.1億 USD0.28%US$45.46+0.46%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
